Search | Clinical Trials Finder

Conditions: Asthma
Interventions: Fluticasone propionate, Placebo, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 41
States / cities: Fountain Valley, California • Huntington Beach, California • Long Beach, California + 36 more

Conditions: Asthma
Interventions: Qvar, Flovent Diskus; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years to 70 Years
Enrollment: 49 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2006
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Persistent Asthma
Interventions: Fp MDPI, FS MDPI, FLOVENT HFA, ADVAIR DISKUS, albuterol/salbutamol HFA; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 758 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 101
States / cities: Birmingham, Alabama • Mobile, Alabama • Pell City, Alabama + 85 more

Conditions: Asthma
Interventions: Fp MDPI, Flovent Diskus, albuterol/salbutamol, Placebo MDPI; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 909 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 129
States / cities: Homewood, Alabama • Goodyear, Arizona • Scottsdale, Arizona + 104 more

Conditions: Allergic Asthma
Interventions: salmeterol, Fluticasone, Placebo; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Asthma
Interventions: FF/UMEC/VI (100/31.25/25) mcg, FF/UMEC/VI (100/62.5/25) mcg, FF/UMEC/VI (200/31.25/25) mcg, FF/UMEC/VI (200/62.5/25) mcg, FF/VI (100/25) mcg, FF/VI (200/25) mcg, Fluticasone/salmeterol (FSC), Albuterol/salbutamol, ELLIPTA DPI, DISKUS DPI, METERED-DOSE INHALER (MDI); Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 2,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 99
States / cities: Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 89 more

Conditions: Asthma
Interventions: FLOVENT (fluticasone propionate) HFA, Placebo HFA; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 6 Months to 12 Months
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2007
U.S. locations: 7
States / cities: Huntington Beach, California • Centennial, Colorado • Jacksonville, Florida + 4 more

Conditions: Asthma
Interventions: ELLIPTA inhaler, Placebo Inhalation Aerosol (MDI); Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 15
States / cities: Huntington Beach, California • Newport Beach, California • Vista, California + 12 more

Conditions: Smoking
Interventions: echocardiogram plus albuterol, airway blood flow plus albuterol, Fluticasone propionate, placebo; Procedure · Drug
Lead sponsor: University of Miami; Other
Eligibility: 25 Years to 75 Years
Enrollment: 31 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: HFA FP MDI, conventional chamber/mask; anti-static chamber/mask; Drug · Device
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 6 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Asthma
Interventions: Fp MDPI, FS MDPI, Advair Diskus, Albuterol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 10
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • St Louis, Missouri + 7 more

Conditions: Asthma
Interventions: Fluticasone propionate/formoterol fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10, Placebo; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 475 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 47
States / cities: Pell City, Alabama • Scottsdale, Arizona • Cypress, California + 42 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 729 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 40
States / cities: Gold River, California • Clearwater, Florida • DeBary, Florida + 31 more

Conditions: Asthma
Interventions: fluticasone, Standard Asthma Discharge Instructions; Drug · Other
Lead sponsor: Rhode Island Hospital; Other
Eligibility: 3 Years to 12 Years
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Asthma
Interventions: Placebo, Fluticasone propionate, BI 54903; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 12 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 37
States / cities: Fountain Valley, California • Fullerton, California • Long Beach, California + 33 more

Conditions: Asthma
Interventions: Placebo, UMEC, Fluticasone Furoate, Albuterol/salbutamol; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 19
States / cities: Tempe, Arizona • Rolling Hills Estates, California • Colorado Springs, Colorado + 15 more

Conditions: Asthma
Interventions: Fluticasone propionate/Formoterol Fumarate 100/10, Fluticasone propionate 100, Formoterol fumarate 10; Drug
Lead sponsor: SkyePharma AG; Industry
Eligibility: 12 Years and older
Enrollment: 357 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 29
States / cities: Birmingham, Alabama • Mission Viejo, California • Orange, California + 26 more

Conditions: Tobacco Abuse Smoke
Interventions: Fluticasone, Placebo; Drug
Lead sponsor: University of Miami; Other
Eligibility: 30 Years to 65 Years
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Asthma
Interventions: BI 671800, Fluticasone propionate placebo, Fluticasone propionate, BI 671800 Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 389 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 40
States / cities: Tucson, Arizona • Cypress, California • Los Angeles, California + 34 more

Conditions: Asthma
Interventions: budesonide/formoterol, fluticasone/salmeterol, mometasone/formoterol, Prednisone; Drug
Lead sponsor: Gelb, Arthur F., M.D.; Individual
Eligibility: 10 Years to 95 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2027
U.S. locations: 1
States / cities: Lakewood, California

Conditions: Asthma
Interventions: BI 671800, Placebo, Montelukast; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 6
States / cities: Denver, Colorado • North Dartmouth, Massachusetts • Plymouth, Minnesota + 3 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: budesonide/formoterol, albuterol/salbutamol, FF/UMEC/VI, Placebo to match budesonide/formoterol, tiotropium, Placebo to match FF/UMEC/VI, placebo to match tiotropium, ELLIPTA, MDI, HandiHaler; Drug · Device
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 40 Years and older
Enrollment: 732 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 42
States / cities: Mobile, Alabama • Bakersfield, California • Sacramento, California + 35 more

Conditions: Asthma
Interventions: Placebo, Fluticasone; Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 50 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Asthma
Interventions: HFA FP MDI; Drug
Lead sponsor: University of Florida; Other
Eligibility: 1 Year to 18 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 1
States / cities: Gainesville, Florida

Search by objective public record fields.

Dose Finding Study on BI54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat® Inhaler in Asthmatic Patients Inadequately Controlled on Short-acting-beta-agonist (SABA) Therapy

Efficacy of QVAR vs Flovent Diskus on Small Airways in Poorly Controlled Asthmatic Adolescents/Adult Patients

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

A Study of the Effectiveness and Safety of Different Doses of Fluticasone Propionate Taken From a Dry Powder Inhaler in Adolescents and Adults Who Have Asthma That is Not Controlled by Asthma Medications Not Containing Steroids

The Effect of Salmeterol on Eosinophil (EOS) Function

A Phase III Parallel Group Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination (FDC) of Fluticasone Furoate+Umeclidinium Bromide+Vilanterol (FF/UMEC/VI) With the FDC of FF/VI in Subjects With Inadequately Controlled Asthma

FLOVENT Hydrofluoroalkane (HFA) In 6-12 Month Old Subjects

ELLIPTA™ vs. MDI Inhaler Preference Study, in Adult Subjects With Asthma

Airway and Pulmonary Vascular Endothelial Function in Healthy Smokers: Effect of Inhaled Glucocorticosteroid Treatment

Impact of Anti-static Chamber/Mask

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone and Formoterol Administered Alone, and Placebo, in Patients With Asthma

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Inhaled Steroids at Discharge After Emergency Department Visits for Children With Uncontrolled Asthma

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

Phase IIb Study of Umeclidinium (UMEC) Bromide Versus Placebo in Subjects With Asthma

Comparison of New Combination Inhaler (FlutiForm HFA MDI 100/10 µg) Versus Fluticasone & Formoterol Administered Alone in Patients With Asthma

Effect of an Inhaled Glucocorticosteroid (ICS) on Endothelial Dysfunction in Cigarette Smokers

BI 671800 ED in Steroid-naive Asthmatic Patients

Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

BI 671800 in Asthmatic Patients on Inhaled Corticosteroids

A Randomized Study, Comparing Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC /VI) Single Inhaler Triple Therapy, Versus Multiple Inhaler Therapy (Budesonide/Formoterol Plus Tiotropium) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Repeated High-dose Inhaled Corticosteroids for Asthma

Effect of Age and Device on Delivery of Fluticasone